GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Medicus Pharma Ltd (OTCPK:MDPLF) » Definitions » Other Long Term Assets

Medicus Pharma (Medicus Pharma) Other Long Term Assets : $0.00 Mil (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Medicus Pharma Other Long Term Assets?

Medicus Pharma's other long-term assets for the quarter that ended in Dec. 2023 was $0.00 Mil.


Medicus Pharma Other Long Term Assets Historical Data

The historical data trend for Medicus Pharma's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medicus Pharma Other Long Term Assets Chart

Medicus Pharma Annual Data
Trend Dec21 Dec22 Dec23
Other Long Term Assets
- - -

Medicus Pharma Quarterly Data
Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Other Long Term Assets Get a 7-Day Free Trial Premium Member Only - - - - -

Medicus Pharma Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.


Medicus Pharma (Medicus Pharma) Business Description

Comparable Companies
Traded in Other Exchanges
Address
100 King Street West, Suite 3400, One First Canadian Place, Toronto, ON, CAN, M5X 1A4
Medicus Pharma Ltd will carry on the business of pharmaceutical drug development focused initially on SkinJect. The objective of SkinJect is developing and commercializing novel microneedle arrays for the purpose of treating certain skin cancers, initially basal cell carcinoma.

Medicus Pharma (Medicus Pharma) Headlines

From GuruFocus

Medicus Pharma Opens the Market

By PRNewswire 10-26-2023